Clinical application of genetically modified T cells in cancer therapy. - Wikidata - awgldk - TriplyDB

Clinical application of genetically modified T cells in cancer therapy.

Clinical application of genetically modified T cells in cancer therapy.

http://www.wikidata.org/entity/Q34511646

about

Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors New Strategies for the Treatment of Solid Tumors with CAR-T Cells Immune targeting of cancer stem cells in gastrointestinal oncology Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia Trial Watch: Adoptive cell transfer for oncological indications Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy Improving the safety of cell therapy with the TK-suicide gene Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.LYRA, a webserver for lymphocyte receptor structural modeling Of Cytometry, Stem Cells and Fountain of Youth.Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors.Serum-derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumor IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.Adoptive Cellular Therapy (ACT) for Cancer Treatment.T-cell therapies for HIV: Preclinical successes and current clinical strategies.Adaptive immunity programmes in breast cancer.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors.CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.Immune checkpoint inhibitors in melanoma

P2860

Q26741260-09978120-1D09-485B-BD92-BFE70A1E94BA Q26748500-F87381D9-F715-4667-B448-4B7E55AB8219 Q26749015-4769BCF5-B411-413E-957C-EF3A14E9E461 Q26781328-0D9E3050-12B1-4CE5-A65F-20EB4894E77A Q26785545-E0427FFC-D2AE-4954-B91E-7EC5A591059B Q26823515-A7D602F0-7753-45F9-B3A4-549803281929 Q26824925-43C4CF60-E7B8-47E4-BE07-8CB003EB9526 Q34477411-32C12DDE-5D5F-4AE2-92DB-155D90B716D9 Q34859794-715116C0-AC71-4E10-B1E8-F3F90B082743 Q35641721-B6482E5E-7032-4E16-872C-D3876914086C Q35718060-4C945A60-6776-408C-8811-B0D416CE8C93 Q35810098-C96BD414-DDA0-472E-A2A9-62F2303F317F Q36330702-AED2BB77-778C-4728-BEB9-D85A83FD36B0 Q36370414-A26461C8-E646-4C4E-837F-AE6771FEE6B7 Q36528333-0E93AFCC-3821-4834-9D11-BCA143390BB2 Q36727794-08E69228-384C-4950-86BE-D7C038CA6E65 Q36884399-16A473F1-D4FC-43A4-A702-F2F09B3BF32F Q37555940-32259FD2-C77B-455A-B0B0-42AE5466272A Q37728639-D2707416-20DC-4EB7-A7CA-3970E427BFA5 Q38707896-5E564DAD-EC93-4D18-B9ED-188EF3DF6A7B Q38719858-5B5E4C91-CA63-43D3-A803-5A3559340787 Q38741113-065A543F-867A-447A-97FF-6D89FDCCBBB6 Q38848219-35537A1E-0EFA-49CA-9330-571F52417C7A Q38856090-C1FBDE16-FA13-43EC-9636-5D0A7783C36F Q38937896-4E0C08C8-2CD5-4F21-A34B-B800B70B0912 Q38987239-870D8B26-6FEC-4F12-8444-F7CC91540680 Q40403393-3B6EAB1C-0897-4287-85D3-DAD1BA7FB489 Q48331916-72B5529E-72AA-4A44-8846-701D4D6DDC49 Q56895914-9EE3EA65-4C07-4510-9AD5-349A5A070E9D

P2860

Clinical application of genetically modified T cells in cancer therapy.

http://www.wikidata.org/entity/Q34511646

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical application of genetically modified T cells in cancer therapy.

@ast

Clinical application of genetically modified T cells in cancer therapy.

@en

Clinical application of genetically modified T cells in cancer therapy.

@nl

type

label

Clinical application of genetically modified T cells in cancer therapy.

@ast

Clinical application of genetically modified T cells in cancer therapy.

@en

Clinical application of genetically modified T cells in cancer therapy.

@nl

prefLabel

Clinical application of genetically modified T cells in cancer therapy.

@ast

Clinical application of genetically modified T cells in cancer therapy.

@en

Clinical application of genetically modified T cells in cancer therapy.

@nl

P1433

Q34511646-6F3B7A20-E9D8-4F42-B1A8-23D40CBC9AED

P1476

Q34511646-B66D0A8A-9FCB-4C49-BF7B-A0F0A6090B2F

P2093

Q34511646-317AA15D-C46B-4540-9809-0822C959A514

Q34511646-7FC7D8AF-9E3D-4079-95FA-D015191CAC1A

Q34511646-952F9E0C-A250-403F-92A2-1C242331B927

Q34511646-CC31C6B1-9580-4F94-9B15-14C32A352639

P2860

Q34511646-0743C637-4825-4CC2-9075-342B6AC170D0

Q34511646-0800FCDB-F440-4662-81CB-71C9D3EA4DDC

Q34511646-0B8456B8-B13C-49DE-9A45-12AD7684BBD1

Q34511646-1091F1BE-FBB1-4ACC-B0EA-D525AC1B9F6E

Q34511646-13B1FDE3-BCA2-443E-859E-8CA242D13426

Q34511646-16319577-AB88-49DD-BF00-8255E9C35279

Q34511646-183494A9-13AA-4AD5-9D73-79E1659AF60F

Q34511646-19F131E0-87FC-401C-A10E-E0DA434245F5

Q34511646-1ED3F60B-1117-43B9-BBCC-C21A7BB89F1E

Q34511646-219806BF-883D-404A-A579-26740CEAC99A

P304

Q34511646-EEE3ABA0-A285-438D-A524-C0A9907F82F0

P31

Q34511646-9FACB317-69FE-4CD8-8BF7-16D01E6AB453

P356

Q34511646-BF8AC1BE-B251-47AF-9BFF-D06507835402

P433

Q34511646-E070A1DB-A719-47B1-BBCE-79D95A9AED3A

P478

Q34511646-D80DB1A9-C974-4A06-9417-83BF5FA0DB99

P577

Q34511646-1DAE2A18-7DAD-48CB-8964-0C51187F91BF

P5875

Q34511646-A53C60E4-05B2-47C1-B7C5-33B036914000

P698

Q34511646-1529BA9A-1078-4291-9C9D-499A0C080E2D

P932

Q34511646-41600952-785C-462D-9D36-D7C5CB6B6D55

P356

P1433

Clinical & translational immunology

P1476

Clinical application of genetically modified T cells in cancer therapy.

@en

P2093

Clare Y Slaney

http://www.w3.org/2001/XMLSchema#string

Jennifer A Westwood

http://www.w3.org/2001/XMLSchema#string

Michael H Kershaw

http://www.w3.org/2001/XMLSchema#string

Phillip K Darcy

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Cancer regression in patients after transfer of genetically engineered lymphocytes

Differential T cell costimulatory requirements in CD28-deficient mice

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

P304

e16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CTI.2014.7

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269711908

http://www.w3.org/2001/XMLSchema#string

P698

25505964

http://www.w3.org/2001/XMLSchema#string

P932

4232070

http://www.w3.org/2001/XMLSchema#string